logo
#

Latest news with #BirenAmin

Aclaris Therapeutics assumed with an Overweight at Piper Sandler
Aclaris Therapeutics assumed with an Overweight at Piper Sandler

Business Insider

time10-07-2025

  • Business
  • Business Insider

Aclaris Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating and $6 price target The shares are currently trading below the company's cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers 'meaningful upside' to Aclaris shares. Piper believes the company's lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

Piper Sandler Remains a Buy on Context Therapeutics (CNTX)
Piper Sandler Remains a Buy on Context Therapeutics (CNTX)

Business Insider

time29-06-2025

  • Business
  • Business Insider

Piper Sandler Remains a Buy on Context Therapeutics (CNTX)

Piper Sandler analyst Biren Amin reiterated a Buy rating on Context Therapeutics (CNTX – Research Report) on June 26 and set a price target of $4.00. The company's shares closed last Friday at $0.66. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Amin is an analyst with an average return of -2.5% and a 40.81% success rate. Amin covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Sarepta Therapeutics, and Viking Therapeutics. Currently, the analyst consensus on Context Therapeutics is a Strong Buy with an average price target of $4.67. The company has a one-year high of $2.75 and a one-year low of $0.49. Currently, Context Therapeutics has an average volume of 249K.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store